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MaOBJECTIVES The intention this PEPCAD-DES (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With
SeQuent Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter) study update was
to demonstrate the safety and efﬁcacy of paclitaxel-coated balloon (PCB) angioplasty in patients with DES-ISR at 3 years.
BACKGROUND In the PEPCAD-DES trial late lumen loss and the need for repeat target lesion revascularization (TLR)
was signiﬁcantly reduced with PCB angioplasty compared with plain old balloon angioplasty (POBA) in patients with
drug-eluting stent in-stent restenosis (DES-ISR) at 6 months. We evaluated whether the clinical beneﬁt of reduced TLR
and major adverse cardiac events (MACE) was maintained up to 3 years.
METHODS A total of 110 patients with DES-ISR in native coronary arteries with reference diameters ranging from 2.5 mm to
3.5 mm and lesion lengths #22 mm were randomized to treatment with either PCB or POBA in a multicenter, randomized,
single-blind clinical study.With a 2:1 randomization, 72 patientswere randomized to the PCB group and 38 patients to the POBA
group. At baseline, there were lesions with at least 2 stent layers in PCB (52.8%, 38 of 72) and POBA (55.3%, 21 of 38) patients.
RESULTS At 36 months, the TLR rates were signiﬁcantly lower in the PCB group compared with the POBA control group
(19.4% vs. 36.8%; p ¼ 0.046). Multiple TLRs in individual patients were more frequent in the POBA group compared
with the PCB group (more than 1 TLR: POBA, 13.2%; PCB, 1.4%; p ¼ 0.021). The 36-month MACE rate was signiﬁcantly
reduced in the PCB group compared with the POBA group (20.8% vs. 52.6%, log-rank p ¼ 0.001).
CONCLUSIONS PCB angioplasty was superior to POBA for the treatment of DES-ISR patients in terms of MACE and TLR
for up to 36 months. There was no late catch-up phenomenon. (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis
With SeQuent Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter [PEPCAD-DES];
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TABLE 1 Selected Basic Demog
the Initial Publication (1)
Baseline cardiovascular risk factors
Age, yrs
Male
Diabetes mellitus
Baseline angiographic data
$2 stent layers
Reference vessel diameter, mm
Minimal lumen diameter, mm
Mehran classiﬁcation: focal
Mehran classiﬁcation: diffuse
Angiographic outcomes at 6 mont
Angiographic follow-up
Late lumen loss target lesion, m
Late lumen loss total segment,
Values are mean  SD or n (%).
PCB ¼ paclitaxel-coated balloon; POB
ABBR EV I A T I ON S
AND ACRONYMS
DES = drug-eluting stent(s)
DES-ISR = drug-eluting stent
in-stent restenosis
LLL = late lumen loss
MACE = major adverse cardiac
event(s)
PCB = paclitaxel-coated
balloon catheter
PES = paclitaxel-eluting
stent(s)
PES-ISR = paclitaxel-eluting
stent in-stent restenosis
POBA = plain old balloon
angioplasty
TLR = target lesion
revascularization
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1696I n the PEPCAD-DES DES (Treatment ofDrug-eluting Stent [DES] In-Stent Reste-nosis With SeQuent Please Paclitaxel
Eluting Percutaneous Transluminal Coronary
Angioplasty [PTCA] Catheter), late lumen
loss (LLL) and the need for repeat target
lesion revascularization (TLR) at 6 months
were signiﬁcantly reduced with paclitaxel-
coated balloon (PCB) angioplasty as com-
pared with plain old balloon angioplasty
(POBA) for drug-eluting stent in-stent reste-
nosis (DES-ISR) (1). However, LLL in the
PCB population was higher than other re-
ported LLL ﬁndings after PCB angioplasty in
bare metal stent ISR (2–5) and DES-ISR
(6–8). This difference may be explained
with the inclusion of restenotic DES with
different antiproliferative drugs. Moreover,SEE PAGE 1701the initial DES implantation in complex lesions with
a high risk of restenosis such as multiple stent layers
(Table 1) may also have contributed to the higher level
of LLL. In this paper, the long-term clinical outcomes
3 years after initial treatment and additional ﬁndings
are reported as well as whether the efﬁcacy of PCB is
different in paclitaxel-eluting stent (PES) restenosis
or non-PES restenosis, whether PCB angioplasty is
equally effective in single-layer versus multilayer
DES-ISR, and whether there is a difference between
diabetic and nondiabetic patients with DES-ISR
when treated with PCB versus POBA.raphic Characteristics and Angiographic Outcomes From
PCB
(n ¼ 72)
POBA
(n ¼ 38)
Pearson’s
Chi-Square p Value
69.8  10.8 64.0  11.3 0.02
52 (72.2) 26 (68.4) 0.68
26 (36.1) 13 (34.2) 0.84
38 (52.8) 21 (55.3) 0.80
2.29  0.51 2.30  0.52 0.95
0.66  0.40 0.62  0.44 0.58
47 (65.3) 25 (65.8) 0.20
25 (34.7) 13 (34.2) 0.41
hs
64 (88.9) 31 (81.6) 0.29
m 0.43  0.61 1.03  0.77 <0.001
mm 0.32  0.55 0.99  0.44 <0.001
A ¼ plain old balloon angioplasty.METHODS
PATIENT POPULATION. From November 2009
to April 2011, 110 patients with restenosis of
sirolimus-eluting stents, everolimus-eluting stents,
or paclitaxel-eluting stents (PES) in a native coronary
artery with the indication for percutaneous coronary
intervention were randomized to treatment with
either PCB or POBA in a multicenter, randomized,
clinical single- blind study. With a 2:1 randomization,
72 patients were treated with PCB and 38 patients
with POBA. Patients with sirolimus-eluting Cypher
stent ISR (Cordis, Warren, New Jersey) or Yukon
stent ISR (Translumina, Hechingen, Germany),
everolimus-eluting Xience stent ISR (Abbott Vascular,
Abbott Park, Illinois), or paclitaxel-eluting Taxus
stent ISR (Boston Scientiﬁc, Natick, Massachusetts),
with a reference vessel diameter of 2.5 to 3.5 mm and
a lesion length less than 22 mm were included.
The inclusion and exclusion criteria, as well as the
study design and the study procedure were reported
previously (1). The protocol was approved by all
ethics committees. All patients gave written informed
consent.
Patients were scheduled for a 6-month angio-
graphic follow-up and clinical follow-up at 12 and
36 months. Angiographic measurements were done
with the CAAS 5.7 software (Pie Medical Imaging BV,
Maastricht, the Netherlands) in the core lab of the
University of Ulm, Ulm, Germany (9,10).
A major adverse cardiac event (MACE) was deﬁned
as a composite of cardiac death, myocardial infarction
attributed to the target vessel, TLR, or a target vessel
total occlusion. TLR was deﬁned as the composite of
TLR by means of percutaneous coronary intervention
or coronary artery bypass grafting. Biochemical evi-
dence of myocardial necrosis was deﬁned as creatine-
kinase myocardial band $3 times the upper normal
limit or a total creatine kinase $3 times the upper
normal limit whenever creatine-kinase myocardial
bandwas not available. Clinical follow-up at 36months
was done by a telephone call with the patient, the pa-
tients’ relatives, or the primary physician. A priori–
deﬁned subgroup analyses were based on paclitaxel-
eluting stent in-stent restenosis (PES-ISR) versus
non–PES-ISR, single-layer versus multilayer DES-ISR,
and diabetic versus nondiabetic patients. Focal pat-
terns of in-stent restenosis were deﬁned as Mehran
classes IA through ID, whereas diffuse patterns were
described by Mehran classes II through IV (11).
STATISTICAL ANALYSIS. Based on the Satterthwaite
t test, a superiority test hypothesis was formulated.
TABLE 2 Accumulated Clinical Outcomes at 6, 12, and 36 Months
PCB
(n ¼ 72)
POBA
(n ¼ 38)
Pearson’s
Chi-Square p Value
6 months
TLR 11 (15.3) 14 (36.8) 0.010
Myocardial infarction* 0 (0.0) 1 (2.6) 0.167
Death, all causes 1 (1.4) 5 (13.2) 0.010
Death cardiac 1 (1.4) 4 (10.5) 0.029
MACE† 12 (16.8) 19 (50.0) <0.001
12 months
TLR 11 (15.3) 14 (36.8) 0.010
Myocardial infarction* 0 (0.0) 2 (5.3) 0.049
Death, all causes 1 (1.4) 5 (13.2) 0.010
Death cardiac 1 (1.4) 4 (10.5) 0.029
MACE† 12 (16.8) 20 (52.6) <0.001
36 months
TLR 14 (19.4) 14 (36.8) 0.046
Repeat TLR
No TLR 58 (80.5) 24 (63.2) 0.021
TLR 1 time 13 (18.1) 9 (23.7)
TLR $2 times 1 (1.4) 5 (13.2)
Myocardial infarction* 0 (0.0) 2 (5.3) 0.049
Death, all causes 6 (8.3) 5 (13.2) 0.423
Death, cardiac 2 (2.8) 4 (10.5) 0.089
Possible thrombotic event 1 (1.4) 4 (10.5) 0.05
MACE† 15 (20.8) 20 (52.6) 0.001
Values are n (%). *Includes 1 patient with CK-MB more than 2 times; 36-month MACE also include
events more than 36 months during the observational period of all patients. †MACE include target
lesion revascularization (repeat percutaneous transluminal coronary angioplastyþ coronary artery
bypass grafting), myocardial infarction, cardiac death.
MACE ¼ major adverse cardiac events; TLR ¼ target lesion revascularization; other abbrevia-
tions as in Table 1.
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1697With a 2:1 randomization (PCB vs. POBA) and an
assumed 6-month in-lesion LLL (primary endpoint)
of 0.20  0.30 mm in the PCB group (4) and
0.80  0.80 mm in the POBA group (2), 64 patients
were calculated for the PCB and 34 for the POBA
group to achieve 90% power. Assuming a dropout
rate of 10%, a total of 71 patients in the PCB group
and 38 in the POBA group were estimated (1). For
logistic regression analyses with 36-month MACE and
12-month TLR as the binary response variables, we
considered a Nagelkerke R2 >0.2 as sufﬁcient for
selected explanatory variables to adequately explain
the variance in the data. Categorical variables were
compared using the Pearson chi-square test or Fisher
exact test, as appropriate. All continuous variables
are given as mean  SD. Differences between pro-
portions and t tests, logistic regression, and univari-
ate analyses were computed with SPSS version 20.0
(IBM, Munich, Germany), whereas sample sizes were
estimated with nQuery Advisor version 7.0 (Statisti-
cal Solutions Ltd., Cork, Ireland).
RESULTS
TLR AND MACE RATES AT 36 MONTHS. Six-month
clinical results showed a signiﬁcant beneﬁt of PCB
compared with POBA (1). At 6 months, TLR rates were
15.3% (11 of 72) versus 36.8% (14 of 38) and MACE
rates were 16.8% (12 of 72) versus 50.0% (19 of 38) (1).
At the 36-month follow-up (Table 2), the TLR rate
remained signiﬁcantly reduced (p ¼ 0.046) in the PCB
group compared with the POBA group (19.4% [14 of
72] vs. 36.8% [14 of 38], respectively). There was a
highly signiﬁcant difference in MACE between the
2 groups (20.8% vs. 52.6%, respectively, p ¼ 0.001).
Furthermore, our MACE-free survival analysis
(Figure 1) revealed a sustained beneﬁt for patients
treated with PCB angioplasty (log-rank, p ¼ 0.001).
Repeat TLR occurred more often in the POBA group
(13.2% of patients [5 of 38] with more than 1 TLR vs.
1.4% in the PBC group [1 of 72]) during the 36 month
follow-up.
There were 4 cases of possible late stent throm-
bosis in the POBA group (10.5%, 4 of 38) during the
3-year follow-up period. In the PCB treatment group,
we recorded 1 possible late stent thrombosis (1.4%,
1 of 72) that led to myocardial infarction. The differ-
ence was borderline signiﬁcant (p ¼ 0.05).
SUBGROUP ANALYSES IN TERMS OF 36-MONTH TLR
AND MACE. Cardiovascular risk factors such as age
and body mass index were analyzed with a univariate
analysis of variance with the treatment group and
various subgroups as ﬁxed factors (Table 3). The onlyclinically and statistically signiﬁcant difference be-
tween subgroups was the age difference between
nondiabetic and diabetic patients in the POBA group
(overall p ¼ 0.005). Subgroup analyses in terms of
36-month TLR and MACE (Table 4) did not reveal any
signiﬁcant differences between non–PES-ISR and
PES-ISR in each treatment group. In the PCB group, the
36-month TLR rates were 22.6% (12 of 51) in the non–
PES-ISR and 9.5% (2 of 21) in the PES-ISR subgroups
(p ¼ 0.25). Likewise, the PCB subgroups of single-layer
stents versus multilayer stents revealing 36-month
TLR rates of 26.5% (9 of 34) and 13.2% (5 of 38),
respectively, did not indicate a signiﬁcant difference
(p ¼ 0.15). There was also no signiﬁcant difference
(p ¼ 0.23) in the PCB subgroups of nondiabetic versus
diabetic patients (15.2%, 7 of 46 vs. 26.9%, 7 of 26).
In contrast, in the POBA group, there was one sig-
niﬁcant difference (p ¼ 0.03) in terms of 36-month
TLR rate between the single-layer versus multilayer
subgroups: 17.6% (3 of 17) versus 52.4% (11 of 21),
respectively.
SUBGROUP ANALYSIS OF FOCAL VERSUS DIFFUSE
DES-ISR PATTERNS. To eliminate the factor of repeat
TABLE 3 Patient Ag
Number of Stent Laye
Non–PES-ISR
(n ¼ 84)
PCB 69.8  11.1
POBA 65.1  12.4
Single Layer
(n ¼ 51)
PCB 71.1  10.1
POBA 63.7  11.6
Nondiabetic
Patients
(n ¼ 71)
PCB 69.6  11.9
POBA 61.2  11.6
Values are mean  SD. p V
BMI ¼ body mass index;
FIGURE 1 Kaplan-Meier Curves for Freedom From MACE in Patients Treated With
PCB or POBA
Kaplan-Meier curves for freedom from MACE in patients receiving either POBA (blue
curves) or PCB angioplasty (green curves). Log-rank, p ¼ 0.001. MACE ¼ major adverse
cardiac events; PCB ¼ paclitaxel-coated balloon; POBA ¼ plain old balloon angioplasty.
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1698TLR, which occurred more frequently in the POBA
group between 12 and 36 months, an additional
intragroup chi-square test was done to investigate the
impact of the initial stenosis pattern on the 12-month
TLR rates (Table 5). There were no signiﬁcant differ-
ences between subgroups of focal versus diffuse
patterns in either treatment group.e and BMI in Patient Groups of Non–PES-ISR/PES-ISR Subgroups,
rs, and Presence of Diabetes Mellitus
Age, yrs BMI
PES-ISR
(n ¼ 26) p Value
Non–PES-ISR
(n ¼ 84)
PES-ISR
(n ¼ 26) p Value
71.0  10.2 0.07 28.1  4.3 27.8  3.5 0.50
60.4  6.4 26.9  3.5 28.6  3.6
Multilayer
(n ¼ 59) p Value
Single Layer
(n ¼ 51)
Multilayer
(n ¼ 59) p Value
69.2  11.4 0.09 28.3  3.9 27.8  4.3 0.64
65.3  11.9 26.9  3.7 27.4  3.5
Diabetic
Patients
(n ¼ 39) p Value
Nondiabetic
Patients
(n ¼ 71)
Diabetic
Patients
(n ¼ 39) p Value
70.9  8.7 0.005 27.4  3.5 29.2  4.6 0.212
70.9  9.1 27.2  3.8 27.3  3.1
alues based on a 2  2 factorial analysis of variance.
PES-ISR¼ paclitaxel-eluting stent in-stent restenosis; other abbreviation as in Table 1.DISCUSSION
Referring to our 36-month results, the TLR rate in the
PCB group was signiﬁcantly reduced as compared
with the POBA group (15.3% vs. 36.8%, p ¼ 0.046).
The MACE rate was also signiﬁcantly lower in the PCB
group (20.8% vs. 52.6%, p ¼ 0.001). Our survival
analysis for MACE revealed a highly signiﬁcant
beneﬁt of PCB over 36 months (log-rank p ¼ 0.001).
To date, there are no other 3-year follow-up results of
PCB angioplasty in DES-ISR patients available so that
a comparison is not possible. Nevertheless, a catch-up
effect between 12 and 36 months could not be
observed, which may be interpreted as sustained
clinical beneﬁts of PCB angioplasty. Upcoming long-
term data with the same PCB technology in the ISAR-
DESIRE-3 (Efﬁcacy Study of Paclitaxel-eluting Balloon,
-Stent vs. Plain Angioplasty for Drug-eluting Stent
Restenosis; NCT00987324) (7) and PEPCAD China
(A Safety and Efﬁcacy Study of Paclitaxel-eluting
Balloon to Paclitaxel-eluting Stent; NCT01622075) (8)
trials will be available in the very near future to
conﬁrm our clinical results.
This study included patients with ISR of PES and
non-PES and a signiﬁcant number of lesions with
more than 1 stent layer to elucidate the effect of PCB
angioplasty for the treatment of “real-world” ISR.
Therefore, the impact on clinical outcomes in sub-
groups of the DES type (PES, non-PES), the number of
stent layers (single, multiple), and the risk factor of
diabetes seemed worthy of further exploration. Our
subgroup analyses for 36-month TLR and MACE did
not show any differences in the PCB group, i.e.,
patients with PES-ISR or multiple stent layers and
diabetic patients did not have less favorable clinical
outcomes. There were signiﬁcantly more TLRs in the
multilayer-stent subgroup when treated with POBA
(p ¼ 0.03). Given the small sample sizes available to
us, the aforementioned ongoing trials with a POBA
control arm (6) may also conﬁrm these ﬁndings for
DES-ISR patients treated with PCB angioplasty.
To date, it remains unclear how the pathophysio-
logical mechanisms of DES-ISR differ from those of
bare-metal stent (BMS) ISR (12,13). Based on the
current literature, DES-ISR is different from bare
metal stent ISR in terms of its temporal presentation,
underlying mechanism, morphological patterns, tis-
sue composition, and response to treatment. There is
evidence that restenosis patterns predict the
outcome (14,15). However, there is also increased
awareness that even a focal DES-ISR is a more
resistant lesion associated with higher MACE rates
(16). It can be suspected that those ISR patterns that
sufﬁciently predict the outcomes after PCB treatment
TABLE 4 Patient Demographic Characteristics and 36-Month MACE Rates According to
the Type of DES-ISR, Number of Stent Layers and Presence of Diabetes Mellitus
PCB (n ¼ 72) POBA (n ¼ 38)
Non–PES-ISR
(n ¼ 51)
PES-ISR
(n ¼ 21) p Value
Non–PES-ISR
(n ¼ 29)
PES-ISR
(n ¼ 9) p Value
Male 38 (74.5) 14 (66.7) 0.50 19 (65.5) 8 (88.9) 0.13
Diabetes 17 (33.3) 9 (42.9) 0.44 11 (37.9) 2 (22.2) 0.39
Dyslipidemia 41 (80.3) 18 (85.7) 0.70 21 (72.4) 6 (66.7) 0.74
Smoker 20 (39.2) 7 (33.3) 0.64 11 (37.9) 6 (66.7) 0.13
Family history of CAD 21 (41.2) 6 (28.6) 0.32 13 (44.8) 4 (44.4) 0.98
36-month TLR 12 (22.6) 2 (9.5) 0.25 10 (34.5) 4 (44.4) 0.59
36-month MACE 13 (25.5) 2 (10.5) 0.13 15 (51.7) 5 (55.6) 0.84
Single Layer
(n ¼ 34)
Multilayer
(n ¼ 38) p Value
Single Layer
(n ¼ 17)
Multilayer
(n ¼ 21) p Value
Male 24 (70.6) 28 (73.7) 0.77 13 (76.5) 13 (61.9) 0.34
Diabetes 14 (41.2) 12 (31.6) 0.40 5 (29.4) 8 (38.1) 0.58
Dyslipidemia 27 (81.8) 32 (84.2) 0.79 15 (88.2) 12 (57.1) 0.04
Smoker 15 (44.1) 12 (31.6) 0.27 6 (35.3) 11 (52.4) 0.29
Family history of CAD 13 (38.2) 14 (36.8) 0.90 8 (47.1) 9 (42.9) 0.80
36-month TLR 9 (26.5) 5 (13.2) 0.15 3 (17.6) 11 (52.4) 0.03
36-month MACE 10 (29.4) 5 (13.2) 0.09 7 (41.2) 13 (61.9) 0.20
Nondiabetic
(n ¼ 46)
Diabetic
(n ¼ 26) p value
Nondiabetic
(n ¼ 25)
Diabetic
(n ¼ 13) p value
Male 32 (69.6) 20 (76.9) 0.50 18 (72.0) 8 (61.5) 0.51
Diabetes 0 (0) 26 (100) — 0 (0) 13 (100) —
Dyslipidemia 36 (80.0) 23 (88.5) 0.36 18 (72.0) 9 (69.2) 0.86
Smoker 16 (34.8) 11 (42.3) 0.53 12 (48.0) 5 (38.5) 0.58
Family history of CAD 8 (39.1) 9 (34.6) 0.70 10 (40.0) 7 (53.8) 0.42
36-month TLR 7 (15.2) 7 (26.9) 0.23 9 (36.0) 5 (38.5) 0.88
36-month MACE 7 (15.2) 8 (30.8) 0.12 13 (52.0) 7 (53.8) 0.91
Values are n (%).
CAD ¼ coronary artery disease; DES-ISR ¼ drug-eluting stent in-stent restenosis; other abbreviation as in
Tables 1 through 3.
TABLE 5 Rates of TLR After Treatment With PCB and POBA According to the
Pattern of Restenosis at Baseline*
Initial pattern
of restenosis
PCB POBA
Focal
(n ¼ 47)
Diffuse
(n ¼ 25) p Value
Focal
(n ¼ 25)
Diffuse
(n ¼ 13) p Value
12-month TLR 14.9%
(n ¼ 7)
16.0%
(n ¼ 4)
0.81 40.0%
(n ¼ 10)
30.8%
(n ¼ 4)
0.58
*Logistic regression analysis with 12-month TLR and treatment group and patterns of restenosis
could only explain 12.9% of the variance in the model (Nagelkerke R2 ¼ 0.129).
Abbreviations as in Tables 1 and 2.
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1699of bare metal stent ISR cannot be applied to the DES-
ISR scenario. More precisely, in the latter lesion type,
the classiﬁcation of lesion types and their risk of
repeat revascularizations may not be sufﬁciently
meaningful for DES-ISR. To reiterate this statement,
it can be stated that in bare metal stent ISR, the
angiographic pattern plays an important role for the
prediction of TLR (16). Latib et al. (15) conﬁrmed
these ﬁndings for DES-ISR, but there are important
differences in contrast to bare metal stent ISR,
whereas restenosis in DES is more often focal (17).
The study reported by Latib et al. described a 1:3
ratio of nonfocal versus a 2:3 ratio of focal DES-ISR
patterns. Our subgroup analysis in terms of the
DES-ISR patterns (focal vs. diffuse) was not predic-
tive of repeat TLR and MACE in the PCB group.
Kastrati et al. (18) found that technical factors may
have an important role in DES-ISR that are associated
with a more focal pattern of restenosis (18). To
investigate this aspect, the documentation of tech-
nical or procedural factors have to be deﬁned a priori
for a proper statistical analysis. Based on our sub-
group analyses, we could not detect a difference in
terms of PCB efﬁcacy in any patient subgroup with
diabetes, multilayer-stent ISR, or PES-ISR. Moreover,
TLR rates were not signiﬁcantly different between
focal and diffuse ISR after treatment with PCB.
Our data imply that the initial pattern of ISR, focal
or diffuse, does not appear as important as in the
case of BMS ISR. Therefore, the classiﬁcation of
ISR, which is mainly based on ﬁndings of BMS ISR
may not be attributable to DES-ISR by implication.
Other factors such as stent expansion and different
tissue composition might predict outcomes of DES-
ISR more accurately than the pattern of restenosis.
Xu et al. (8) commented that the use of PCB in ISR
offers the clinical beneﬁt of drug delivery to the
lesion site without the need for additional metal
layers. This, in turn, seems highly attractive for rea-
sons such as less mechanical irritation of a permanent
implant and especially reducing dual antiplatelet
therapy duration. We believe that in the affected
patient population, it is beneﬁcial to reduce the dual
antiplatelet therapy duration to a minimum, provided
that there are no additional bare metal stents or DES
implanted during the primary intervention. In case
noncoronary interventions, vascular reconstructions,
or other nonvascular surgical procedures are indi-
cated, the risk of stent thrombosis associated with
PCB angioplasty without additional stenting is very
low or negligible in an all-comers patient population
(18). The current dual antiplatelet therapy recom-
mendation for PCBs with Paccocath technology is
4 weeks.STUDY LIMITATIONS. The study was powered for the
primary endpoint, i.e., in-lesion LLL and not for the
subgroup analyses. Besides the pre-planned subgroup
analyses for diabetic patients and the DES-ISR type
(PES vs. non-PES), some post-hoc analyses could not
be conducted (i.e., the single- vs. multiple-stent layer
subpopulations). Consequently, some of the resulting
subgroup patient numbers are low, in particular for
the subgroup of PES-ISR. Hence, our results may be
cautiously applied to clinical practice despite the fact
PERSPECTIVES
WHAT IS KNOWN? In PEPCAD-DES, PCB angio-
plasty was superior to POBA in terms of LLL, MACE,
and TLR at 6 months for the treatment of DES-ISR.
WHAT IS NEW? This is the longest available
follow-up of DES-ISR patients treated with PCBs.
At 36 months, the clinical superiority (MACE, TLR)
of drug-coated over uncoated balloons remained.
There was no late catch-up phenomenon nor did any
subgroup have signiﬁcantly higher clinical event
rates.
WHAT IS NEXT? A comparison with other trials in
DES-ISR patients treated with PCB angioplasty or PES
may conﬁrm our ﬁndings in the very near future.
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1700that they are, from our point of view, hypothesis
generating. The trial design was single blind and not
double blind with the use of an uncoated balloon in
the POBA group, resulting in different lengths of the
study balloons. We did not use intravascular ultra-
sound to evaluate stent underexpansion or neointimal
proliferation. It is important to point out that to
perform meaningful multi- or univariate analyses or
logistic regressions, our sample sizes were too small.
CONCLUSIONS
Long-term results after the treatment of DES-ISR with
PCB angioplasty indicate that 3-year clinical event
rates remain signiﬁcantly lower compared with those
associated with POBA. The presented subgroup ana-
lyses of the randomized, multicenter PEPCAD-DES
trial revealed that treatment with PCB appears to
be equally effective in PES-ISR and non–PES-ISR,
in multilayer/single-layer DES-ISR, and in diabetic
versus nondiabetic patients.
A careful projection of our results into clinical
practice may also allow the statement that the pattern
of DES-ISR is not predictive of repeat vascularization
after PCB treatment at mid-term.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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